Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (LTRN) announced positive preclinical results for its drug candidate LP-184 against glioblastoma (GBM). The study showed LP-184 inhibits tumor growth by over 106% and extends survival in mice by 27% compared to controls. Conducted with Johns Hopkins, the findings support LP-184's potential in treating GBM, particularly in patients unresponsive to standard therapies. Lantern plans to refine dosing regimens and strengthen its FDA orphan drug application. This signifies a step towards addressing critical gaps in GBM treatment, benefiting patients with varying tumor profiles.
Lantern Pharma (LTRN) announced that its abstract, titled 'LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects', has been accepted for presentation at the AACR Virtual Special Conference on Pancreatic Cancer on September 29-30, 2021. The abstract highlights LP-184's promising efficacy in pancreatic cancer models, especially with DNA repair deficiencies. The drug has received Orphan Drug Designation from the FDA for pancreatic cancer treatment.
Lantern Pharma (LTRN) announced that the FDA has granted Orphan Drug Designation for its drug candidate LP-184, aimed at treating pancreatic cancer. This designation will provide seven years of market exclusivity, tax credits, and other benefits, enhancing the potential for LP-184's development. LP-184 has shown significant tumor shrinkage in preclinical models, highlighting its promise. The drug targets specific pancreatic cancer patients with certain biomarkers, potentially improving treatment outcomes in a cancer with a poor survival rate of 7.9% over five years.
Lantern Pharma (LTRN) reported its Q2 2021 financial results, highlighting significant advancements in its cancer therapy pipeline. The company aims to expedite drug development using its RADR® A.I. platform, with promising data from its LP-184 program targeting pancreatic cancer and other malignancies. Cash reserves surged to $79.6 million, aided by a $69 million public offering. However, R&D expenses increased to $1.16 million, contributing to a net loss of $2.32 million, or $0.21 per share. Upcoming milestones include clinical trials for LP-300 and data from collaborations with leading cancer research institutions.
Lantern Pharma (LTRN) announced an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven (LP-100) from Allarity. This transaction also grants Lantern exclusive licensing to Allarity's companion diagnostic. The company is set to assume full control over LP-100's clinical development, which targets prostate and bladder cancer patients with ERCC2/3 gene mutations. Initial Phase 2 trial data showed a median overall survival of 12.5 months for treated patients. Lantern plans to expand its trials and aims for potential regulatory approvals in the US and EU.
Lantern Pharma (NASDAQ: LTRN) will host a conference call on July 29, 2021, at 4:30 p.m. ET to discuss its financial and operating results for Q2 2021, ending June 30, 2021. CEO Panna Sharma will lead the call with management team members. The call can be accessed via toll-free numbers and will be available for replay until August 29, 2021. Lantern Pharma is focused on oncology and utilizes its proprietary RADR® A.I. platform to enhance drug discovery and identify suitable patient profiles for its therapeutics.
Lantern Pharma (LTRN) announced promising preclinical data regarding its drug candidate, LP-184, in collaboration with the Fox Chase Cancer Center. The data showed over 90% tumor shrinkage in pancreatic cancer mouse models within 8 weeks, contrasting with significant tumor growth in untreated mice. The study also indicated that LP-184 is effective against various pancreatic cancer cell lines and patient-derived xenograft models, suggesting its potential for targeted therapy. Additionally, the research validated the role of PTGR1 in enhancing the drug's efficacy, supporting future trials aimed at genetically defined patient populations.
Lantern Pharma Inc. (LTRN) reported its financial results for Q1 2021, highlighting significant advancements in its oncology drug pipeline. The company expanded its RADR® A.I. platform to over 4.6 billion datapoints, nearly a 16-fold increase since its IPO. Lantern's collaboration with Actuate Therapeutics aims to improve insights into the 9-ING-41 drug candidate using RADR® technology. As of March 31, 2021, cash and cash equivalents rose to $81.4 million, while the net loss increased to $2.45 million, consistent with the previous year. The company remains focused on advancing clinical trials and potential partnerships.
Lantern Pharma (NASDAQ: LTRN) announced a research and development collaboration with Actuate Therapeutics to utilize its RADR® AI platform in the advancement of Actuate's 9-ING-41 drug candidate, a GSK-3β inhibitor undergoing multiple Phase 2 trials. The collaboration aims to enhance drug development through machine learning and oncology datasets, potentially generating joint intellectual property. Lantern expects its RADR® platform to surpass 10 billion oncology data points within a year, enhancing its capabilities in patient stratification and drug discovery.
Lantern Pharma (LTRN) announced that its RADR® AI platform has surpassed 4.6 billion datapoints, marking a 16-fold increase over the past year. This advancement enhances the platform's drug discovery capabilities across various cancers, focusing on personalized oncology therapeutics. CEO Panna Sharma highlighted the importance of this milestone in speeding up drug development and increasing collaboration opportunities in the biopharma sector. Additionally, Lantern filed two new patents to protect its innovations in AI-driven drug development.